智通财经APP获悉，基石药业-B(02616)再涨超6%，月内累计涨幅已超25%。截至发稿，涨5.03%，报6.68港元，成交额1.02亿港元。
消息面上，2月23日，基石药业宣布，其PD-L1抗体舒格利单抗针对III期非小细胞肺癌(NSCLC)的新适应症，已正式取得英国药品和医疗保健用品管理局(MHRA)的批准。此次获批是该适应症继2024年7月获得欧盟委员会(EC)许可之后，在欧洲核心市场取得的又一关键突破。
此外，基石药业核心资产CS2009用于晚期实体瘤的II期临床试验IND申请近期获得FDA批准。CS2009(PD-1/VEGF/CTLA-4三特异性抗体)用于晚期实体瘤的II期新药临床试验申请(IND)获美国食品药品监督管理局(FDA)批准，标志着这一创新免疫疗法的全球开发取得重要进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.